Andolast, also known as CR-2039, an anti-allergic agent for the treatment of bronchial asthma, chronic obstructive pulmonary disease (COPD). Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis. Andolast proved to be significantly more effective than placebo in improving airflow, and in controlling asthma symptoms both during day and night.

132640-22-3

C15H11N9O

333.31

CR-2039;CR 2039;CR2039;Andolast

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years